臺灣博碩士論文加值系統

5-Fluorouracil(5-FU)在臨床上為治療大腸癌(colon cancer)最有用的藥物，由於直接服用或是經由靜脈注射，經由肝臟的代謝時，對生體的毒害相當的大。近來有相當多關於5-FU藥物載體的研究，絕大部分皆是高分子劑型的開發，我們試著利用蒙脫石特有的層間性質與生物惰性，做為無機藥物載體，經由消化道使5-FU能在大腸中做長效型的釋放(sustained release)，以減低5-FU的毒性。我們試著製備出適合5-FU與蒙脫石複合物，並試著找出5-FU插入或吸附於蒙脫石的條件，並以XRD、FT-IR、UV/Vis、DTA/TGA進一步証實蒙脫石的插入行為，以利之後的釋放結果分析。
經一系列之分析，求得5-FU插入蒙脫石之適當條件為：
(1) 浸泡時間：2小時
(2) 反應溫度：80℃
(3) 反應pH值：11.6
(4) 反應之5-FU起始濃度：1.185wt%
當5-FU與蒙脫石複合物於模擬消化道模式釋放時，在5th至24th小時模擬大腸釋放結果發現，所釋放的5-FU濃度每小時可達到相當於有效治療濃度的1/20。爾後利用WiDr大腸癌細胞與5-FU/蒙脫石複合物及其釋放液進行細胞培養實驗，利用MTT Assay群落比色分析與TEM觀察細胞切片，可証明5-FU的釋放作用足以有效抑制大腸癌細胞增生繁殖，而達到有效的治療效果。

In the recent decade, the most useful drug for the therapy of colon cancer is 5-Fluorouracil(5-FU). It has been reported to have considerable toxicity administered by intravenous injections or via alimentary treat. Though many materials have developed for drug carrier of 5-FU, there was no clinically acceptable carrier for 5-FU till now. Montmorillonite, one of clay minerals, consists of hydrated aluminum silicates that are fined grained and usually have a large space between the layers. Isomorphous substitution of cations is common. We try to intercalate 5-FU into interlayer of montmorillonite through ion-exchange. Montmorillonite with 5-FU intercalation is expected to achieve in-situ release for colon cancer therapy. In the study, 5-FU was dissolved in 100ml distilled water as 5-FU solution. Purified montmorillonite powder will soak in 5-FU solution for a period of time at different pH value and temperature. The intercalated amount of 5-FU in montmorillonite is measured and confirmed by scanning differential thermal (SDT) analysis and ultraviolet visble analysis (UV) analysis. The results showed that 4g purified montmorillonite soaked in 0.6% 5-FU solution for 2 hours had an optimum condition for intercalation. The total amount of 5-FU in montmorillonite is about 87.5mg in 4g montmorillonite.
In the gastrointestine(GI) simulated releasing model, the releasing amount of 5-FU in 5-FU/Mont. Composite, which is capsulated with gelatin between 5th to 24th hour, could achieve 1/20 the clinical effective concentration and thoroughly in vitro inhibition to WiDr. In use of the method of MTT assay, population analysis and transmission electron microscope (TEM) analysis, we could confirm the proliferous inhibition of WiDr by the releasing 5-FU and effective therapy to colon cancer.

摘要-------------------------------------------------------------------------------------Ⅰ
英文摘要------------------------------------------------------------------------------Ⅱ
目錄-------------------------------------------------------------------------------------Ⅲ
圖目錄---------------------------------------------------------------------------------Ⅴ
表目錄---------------------------------------------------------------------------------Ⅷ
第一章 緒論-------------------------------------------------------------------------1
1-1 前言---------------------------------------------------------------------------------1
1-2 文獻回顧---------------------------------------------------------------------------1
1-2-1 5-Fluorouracil(5-FU)合成----------------------------------------------2
1-2-2 5-FU之藥物特性及發展---------------------------------------------2
1-3 研究目的-------------------------------------------------------------------------10
第二章 理論基礎------------------------------------------------------------------11
2-1 蒙脫石的純化、理論構造及應用------------------------------------------11
2-1-1 蒙脫石的分離純化----------------------------------------------------11
2-1-2 蒙脫石的理論構造及礦物特性------------------------------------12
2-2 擴散理論(Diffusion theory) -------------------------------------------------------17
2-2-1 費克(Fick)第一定律----------------------------------------------------------17
第三章 實驗步驟與方法--------------------------------------------------------19
3-1 實驗儀器-------------------------------------------------------------------------19
3-2 實驗藥品-------------------------------------------------------------------------20
3-3 實驗方法及流程---------------------------------------------------------------21
3-3-1 蒙脫石之純化-----------------------------------------------------------21
3-3-2 純化後蒙脫石陽離子交換量之測定------------------------------23
3-3-3 5-FU/蒙脫石複合物之製備-------------------------------------------25
3-3-4 5-FU/蒙脫石複合物性質分析---------------------------------------27
3-3-5 5-FU/蒙脫石複合材料之藥物釋放---------------------------------30
3-3-5.1 5-FU/蒙脫石在不同pH值下之釋放------------------------30
3-3-5.2 腸胃道模擬釋放(Gastric-intestine simulated releasing)--32
3-3-6 細胞活性測試與生物電子顯微鏡觀察---------------------------34
3-3-6.1 細胞群落分析(Population analysis) -------------------------34
3-3-6.2 MTT藥物濃度測試---------------------------------------------36
3-3-6.3 TEM切片觀察---------------------------------------------------38
第四章 結果與討論--------------------------------------------------------------41
4-1 5-FU/蒙脫石複合物之製備--------------------------------------------------41
4-1-1 陽離子交換量(CEC)之測定-----------------------------------------41
4-1-2 5-FU插入或吸附於蒙脫石之適當反應條件-------------------42
4-1-3 5-FU/蒙脫石複合物之材料分析-----------------------------------44
4-2 藥物釋放曲線-------------------------------------------------------------------46
4-2-1 5-FU/蒙脫石複合物之釋放曲線---------------------------------46
4-2-2 5-FU/蒙脫石以Gelatin膠囊包覆之釋放曲線-----------------46
4-2-3 Gelatin膠囊與蒙脫石之作用機制-------------------------------48
4-2-4 模擬人體消化道之藥物釋放(GI-Simulated Releasing)------49
4-3 細胞活性實驗-------------------------------------------------------------------49
4-3-1 群落分析(Population analysis) -------------------------------------49
4-3-2 MTT測試(MTT test) ------------------------------------------------50
4-3-3 穿透式電子顯微鏡分析(TEM analysis) ------------------------50
第五章 結論------------------------------------------------------------------------83
第六章 未來展望------------------------------------------------------------------85
第七章 參考文獻------------------------------------------------------------------86

1. Heidelberger C, Chaudhuari NK, Danenberg P, el al. Fluorinated pyrimidines: a new class of tumor inhibitory compounds. Nature 179(1957), 663-666
2. Meropol NJ, Creaven PJ, Petrelli NJ. "Metastatic colorectal cancer: advances in biochemical modulation and new drug development", Seminar Oncology, 22(1995), 509-524
3. Wolmark N. Rockette H. Mamounas E. Jones J. Wieand S. Wickerham DL. Bear HD. Atkins JN. Dimitrov NV. Glass AG. Fisher ER. Fisher B., "Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes'' B and C carcinoma of the colon", Journal of Clinical Oncology, 17(11): (1999), 3553-3559
4. Kubota T. Kase S. Otani Y. Watanabe M. Teramoto T. Kitajima M., "Interferons alpha-2a and beta increase the antitumor activity, detected by MTT assay, of5-fluorouracil against experimental and clinical human gastrointestinal carcinomas", Anticancer Research, 17(1997), 725-728
5. Kase S. Kubota T. Watanabe M. Furukawa T. Tanino H. Ishibiki K. Teramoto T. Kitajima M., "Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo", Anticancer Research, 13(1993), 369-374
6. Fischel JL. Formento P. Berlion M. Berille J. Gioanni J. Bizzari JP. Milano G., "Sequence-dependent cytotoxic effects of the combination of a new nitrosourea, fotemustine, with 5-fluorouracil plus folinic acid", Cancer Chemotherapy and Pharmacology, 8(1991), 448-454
7. Kano Y. Akutsu M. Tsunoda S. Ando J. Matsui J. Suzuki K. Ikeda T. Inoue Y. Adachi K. "Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro", British J. of Cancer, 74(1996), 704-710
8. Kano Y. Akutsu M. Tsunoda S. Suzuki K. Yazawa Y., "In vitro sequence-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines", Cancer Chemother Pharmacol, 37(1996), 525-530
9. Ishihara M. Kubota T., "Combined antitumour activity of mitomycin C, 5-fluorouracil and interleukin-2 against human colon cancer cells", Anticancer Research, 19(1A): (1999), 313-316
10. Kase S. Kubota T., "The modulation by L-leucovorin of 5-fluorouracil antitumor activity on human colon carcinoma cells in vitro and in vivo", Surgery Today, 23(7): (1993), 615-620
11. Ducreux M. Ychou M. Seitz JF. Bonnay M. Bexon A. Armand JP. Mahjoubi M. Mery-Mignard D. Rougier P. "Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer", Journal of Clinical Oncology. 17(9): (1999), 2901-2908
12. Lorenz M. Muller HH. Randomized, "Multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma", Journal of Clinical Oncology. 18(2): (2000), 243-254,
13. Hreshesky WJM, Bjarnson GA., Circadian cancer therapy, J. of Clinical Oncology, 11(1993), 1403-1417
14. Leichman CG, Fleming TR, Muggia FM, J. of Clinical Oncology, 13(1995), 1303-1311
15. Blank CD, J. of Clinical Oncology, 15 (1997), 915-920
16. Roche, Mannual of Roche Fluorourcail
17. Liu G, Fressen E, Fitch MI, Warner E, J. of Clinical Oncology, 15 (1997), 110-115
18. Diasio RB, Harris BE, Clinical pharmacology of 5-fluorouracil. Clinical Pharmacokinetics, 16 (1989), 215-237
19. Meropol NJ. Oral fluoropyrimidine in the treatment of colorectal cancer. European J. Cancer, 34 (1998), 1509-1513
20. Milano G, McLeod HL, Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment, European J. Cancer, 36 (2000), 37-42
21. Suguru Kase, Tetsuro Kubota, Anticancer Research, 13(1993), 369-374
22. Blanco M. D., Garcia O., Trigo R. M., Teijon J. M., Biomaterials, 17 (1996), 1061-1067
23. Gokce M., Akada T. F., kiremitci-Gumusderelioglu M., Biomaterials, 17 (1996), 941-949
24. Garcia O., Trigo R. M., Blanco M. D., Teijon J. M., Biomaterials, 15 (1994), 689-694
25. Qin W., yan L. and Juan Z., Chinese J. of Biomedical Engineering, 14, (1995), 11-15
26. Fang Y. E., Cheng Q., Lu X. B., Journal of App. Polymer Sci., 68(1998), 1751-1758
27. Nakamura T., Journal of Biomediacal Material Research, 28(1994),17-25
28. Macrter W.J. and Brousseau R., Cem. and Conc.Res.,20:6, (1990), 891-900
29. Cristina Volzone, Materials Chemistry and Physics, 47(1997), 13-16
30. 孫澄源，陶瓷製造技術，中華民國陶業研究學會，1992
31. 程道腴，精密陶瓷原料燒結前加工法，徐氏基金會，1992
32. Franchi M. Bramanti E. Bonzi LM. Orioli PL. Vettori C. Gallori E., "Clay-nucleic acid complexes: characteristics and implications for the preservation of genetic material in primeval habitats. Origins of Life & Evolution of the Biosphere", 29(3): (1999), 297-315
33. Ertem G. Ferris JP., "Formation of RNA oligomers on montmorillonite: site of catalysis. Origins of Life & Evolution of the Biosphere", 28(4-6): (1998), 485-99
34. Oya A., Kimura N. and Ohashi F., Applied Clay Science, 6(1992), 301-310
35. Morri RJ. Williams DE. Luu HA. Holmes CF. Andersen RJ. Calvert SE. "The adsorption of microcystin-LR by natural clay particles", Toxicon, 38(2): (2000), 303-8
36. 王守明，膨礦土及其加工技術，礦產保護與利用，第二期，(1992)，21-28
37. 杜伯雄，海藻酸鈉/蒙脫石複合物之農業應用，台灣大學材料科學與工程學研究所碩士論文，(1999)，15-37
38. Grimm R.E., Clay Minerology , McGraw-Hill, New York, (1968)
39. Zvyagin,B.B.,and Pinsker, Z.G.,"Structure of montmorillonite", C.R. Acad. Sci.U.R.S.S. (1949), 68, 65-67, 505~508,
40. Mering J. Glaeser R.,"Cations echangeables dans montmorillonite ", C.R.Bull, (1953), 5, 61~72
41. Ralph W. G., Wyckoff, "Crystal Structures",(1963), 4, 365-366
42. Crim R.E., Bradley W.F., J. Am. Ceram. Soc., 23(1940),242-248
43. Takeshi H., Y. Uno, Mineral Soc. Japan, Spec.,1, 98(1971)
44. McCabe Smith Harriott，呂理平譯，單元操作，高立出版社，(1985)，845-888
45. 葉和明，單元操作，三民書局，(1971)，611-653
46. 邯鄲工業學校，物理化學與陶瓷物理化學，輕工業出版社，(1986)，352-419
47. Bremner J. M., "Total nitrogen, inorganic forms of nitrogen, Organic forms of nitrogen, nitrogen availability indexes. In C.A. Black et al.(ed.) Methods of Soil Analysis", Part 2: 1149-1255, 1324-1348
48. 陳家全，李家維，楊瑞森，生物電子顯微鏡學，國科會精密儀器中心，(1991)，23-81
49. Boyd S. A., J.F. Lee and M. M. Mortland, "Attenuating organic contaminant mobility by soil modification", (1988)